Search Results for “biotechnology” – Page 11 – media

MAXVAX’s recombinant herpes zoster vaccine (CHO cell) enrolled in Phase III clinical trials

On July 13, the Phase III clinical trial of recombinant herpes zoster vaccine (CHO cell) of Chengdu MAXVAX Biotechnology Co., Ltd (MAXVAX) completed the enrollment of the first subject in Liangyuan District, Shangqiu City, Henan Province, marking the successful start of the Phase III clinical trial of the recombinant herpes zoster vaccine of MAXVAX. The vaccine product adopts recombinant protein technology route and carries independently developed new adjuvant system MA105, which is the first innovative vaccine with composite adjuvant system with independent intellectual property rights to enter phase Ⅲ clinical trial in China. The results of Phase I and Phase II clinical trials show that it has good safety, tolerability and immunogenicity. Phase III clinical trials will further verify the safety, immunogenicity and protective efficacy of the vaccine in a large sample of people, providing key data for the product’s marketing application. About Herpes Zoster Vaccine Herpes zoster is a ...
- Source: drugdu
- 59
- July 16, 2024
Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity

Chinese pharmaceutical manufacturer Innovent Biologics has transferred the licence for Fucaso (equecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy, to its development and commercialisation partner IASO Biotechnology (IASO Bio). Although the companies did not disclose the sale price of the deal, Innovent stated that it would use the proceeds to acquire an 18% stake in IASO Bio. Following the agreement, IASO Bio holds global commercial rights to Fucaso. Fucaso is a B-cell maturation antigen (BCMA) targeting CAR T-cell therapy. It was approved by China’s National Medical Products Administration (NMPA) as a fourth-line therapy to treat relapsed and/or refractory multiple myeloma (r/r MM), last month. The companies have also received an investigational new drug (IND) application for Fucaso as a treatment for r/r MM patients who have undergone up to two lines of prior therapies and are refractory to Revlimid (lenalidomide). Fucaso has also received orphan drug, medicine advanced therapy ...
- Source: drugdu
- 86
- July 9, 2024
API China

Organizer: Reed Sinopharm Exhibitions Date: October 16-18, 2024 Venue: No. 1399 Huizhan 1st Road, Baqiao District, Xi’an, Shaanxi Province Exhibition hall：Xi’an International Convention and Exhibition Center Product range: Pharmaceutical APIs, Pharmaceutical Excipients, Natural Extracts, Chemical Reagents, Intermediates, Fine Chemical Raw Materials, Key Raw Materials, Food Ingredients and Additives, Veterinary Drug Raw Materials, Feed Ingredients and Additives, Health Product Ingredients and Additives, Biotechnology, Pharmaceutical R&D Services, Contract Manufacturing Services, Registration and Pharmaceutical Services, Training Services Exhibition Introduction: As the longest-running exhibition in China’s pharmaceutical industry, API China – China International Pharmaceutical API Exhibition was first held in 1968. The exhibits cover more than 50,000 types of APIs in 24 categories, as well as all auxiliary materials, functional ingredients, internal and external packaging materials, production and testing equipment required for the production of pharmaceuticals and health products.
- Source: drugdu
- 164
- June 19, 2024
Sridhar Babu inaugurates Innovera’s new site in New Jersey

Minister Sridhar Babu inaugurated Innovera Pharma’s latest site in New Jersey, USA, during his recent visit. The new facility is expected to expand Innovera Pharma’s research, development, and production capabilities. The roots of this collaboration were established during a key meeting at the World Economic Forum (WEF) in Davos, Switzerland wherein Telangana CM Revanth Reddy and Sridhar Babu led a delegation earlier this year. These discussions paved the way for the company to invest in Telangana. Solidifying this partnership, within 30 days of the announcement, a ceremony was held on February 22, 2024, in Suryapet, Telangana. This event marked the commencement of a project aimed at enhancing local manufacturing capabilities and infrastructure. The partnership highlights how regional governments can support enterprises in scaling their operations globally. By fostering such alliances, this active partnership not only strengthens Innovera’s global presence but also reinforces Telangana’s strides to develop the pharmaceutical and biotechnology ...
- Source: drugdu
- 126
- June 15, 2024
Iran PHARMA

Organiser：Iran Pharmaceutical Industry Federation Time：October 2nd to 4th, 2024 address：Mashhad Exhibition and Convention Center, Iran Exhibition hall：Mashad Fair Ground Product range: Pharmaceutical machinery: preparation production equipment, pharmaceutical water equipment, traditional Chinese medicine processing equipment, refrigeration equipment, etc Packaging equipment and materials: aluminum-plastic packaging machine, filling machine, tablet press, labeling machine, inkjet printer, anti-counterfeiting printing and packaging and packaging production line, bar code composite technology equipment, adhesive printing and packaging equipment, plastic packaging products, packaging container forming, filling and sealing machine, cartoning packaging machine, bag packaging machine, multi-function bottled packaging machine, glass packaging products and medicinal packaging materials production equipment, etc Laboratory equipment/analysis and testing: laboratory equipment and devices, laboratory consumables, chemical reagents, biochemical/analytical instruments, biotechnology analysis and testing instruments, pharmaceutical testing equipment, food analysis and testing instruments, pharmaceutical industry analysis instruments, etc Fluid equipment: sanitary pumps, valves, fluid engineering, pipes and pipe fittings, microfiltration, ultrafiltration, etc Clean system: clean air ...
- Source: drugdu
- 97
- June 14, 2024
Astellas Confirms FDA Acknowledgement of Zolbetuximab Resubmission

Mike Hollan The drug had previously been submitted, but required resubmission due to production issues. FDA acknowledged that Astellas has resubmitted zolbetuximab for a Biologics License Application (BLA).1 The drug is a first-in-class claudin 18.2-targets monoclonal antibody and is designed to treat various forms of gastric cancer. According to a press release issued by Astellas, FDA has set November 9, 2024, as its new target action date. The drug had been previously submitted, but had to be resubmitted after Astellas received a complete response letter from FDA in January, 2024. While the agency did not state any issues with the clinical data, efficacy, or safety of the drug, it required resubmission due to third-party manufacturing deficiencies. Astellas resubmitted the drug on May 9, 2024, but only just announced confirmation from FDA. In a press release, Astellas’ senior vice president and head of immuno-oncology development Moitreyee Chatterjee-Kishore, PhD, MBA, said, “Astellas ...
- Source: drugdu
- 119
- June 7, 2024
NHS platform announced to accelerate personalised cancer vaccine clinical trials

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines The NHS has announced that it has treated its first patient in England with a personalised cancer vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad (CVLP). Following the launch of the trial, thousands of cancer patients in England are set to be fast-tracked to access personalised cancer vaccines to help find new life-saving treatments. In partnership with Genomics England, the NHS CVLP will help speed up access to mRNA-personalised cancer vaccine clinical trials for cancer patients while accelerating the development of cancer vaccines as a form of treatment. With 30 hospitals in England already signed up to participate, the scheme intends to collaborate with the pharmaceutical industry to include patients across many cancer types. Taking place in several NHS trusts across the country to treat different types of ...
- Source: drugdu
- 72
- June 4, 2024
Degron Therapeutics, Takeda Ink Exclusive License and Collaboration Agreement to Develop Molecule Degraders Targeting Multiple Indications

Don Tracy, Associate Editor Joint venture expected to utilize Degron’s GlueXplorer platform to identify, validate, and optimize molecular glue degraders. Degron Therapeutics announced that it has agreed to terms on a collaboration with Takeda, which will utilize its GlueXplorer to develop molecular glue degraders targeting oncology, neuroscience, and inflammation. Upon completion of the initial stages, Takeda will take over for further development and commercialization. Under terms of the deal, Degron will receive an upfront payment, with the opportunity to receive up to $1.2 billion in milestone payments and tiered royalties on sales. The deal also includes an equity investment by Takeda in Degron and the option to expand to additional targets.1 “We are excited to collaborate with Takeda, expanding the use of our platform into new therapeutic areas,” said Lily Zou, PhD, co-founder, CEO, Degron Therapeutics, in a press release. “Degron’s differentiated and powerful GlueXplorer platform has been validated by ...
- Source: drugdu
- 75
- May 28, 2024
Pharmed Vietnam 2024

Organiser：Adpex JSC Time：11- 14 September 2024 address：Lawrence S. Ting Building 801 Nguyen Van Linh Parkway, Dist. 7 Ho Chi Minh City Vietnam Exhibition hall：Saigon Exhibition & Convention Center Product range: Medical Products Exhibition area: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institutions and laboratory technology equipment, medical information and technology exchange, beauty equipment Analytical Instruments Exhibition area: Optical analysis instruments, mass spectrometers, spectrometers, chromatographs, spectrometers, electrochemical analysis instruments, X-ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, all kinds of portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition analysis instruments, injection analysis instruments and other general analytical instruments Laboratory Equipment Exhibition area: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, ...
- Source: drugdu
- 167
- May 27, 2024
Focusing on intelligent pharmaceutical manufacturing, Nanchang, Jiangxi, promotes high-quality development of the biopharmaceutical industry

Recently, when I walked into the disposable medical supplies production workshop of Nanchang Ruiao Jucheng Biotechnology Co., Ltd. located in Nanchang Economic and Technological Development Zone, Jiangxi Province, I saw the workers on the intelligent production line skillfully carrying out product inspection, assembly, packaging and other tasks, and the scene was full of bustling production. It is understood that Nanchang Ruiao Jucheng Biotechnology Co., Ltd. is a high-tech enterprise specializing in biotechnology research, development and production . “At present, the company’s production orders have been scheduled until November, and the products are in short supply. In order to meet the production needs of orders, we have carried out targeted expansion by adding new production lines.” Zhou Bin, chairman of Nanchang Ruiao Jucheng Biotechnology Co., Ltd., introduced. At present, the company has built instrument production workshops and reagent production workshops, which can produce 100 flow cytometers and 5 million diagnostic kits ...
- Source: drugdu
- 82
- May 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.